Disease · MONDO_0005097
Comparisons in its trials18
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 18 of 18
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Afatinib vs Erlotinib: Number of Participants With Disease Control According to RECIST 1.1 | 201 of 398 | 157 of 397 | 795 | NCT01523587 | Trial comparisons |
| Afatinib vs Erlotinib: Number of Participants With Objective Response According to RECIST 1.1 | 22 of 398 | 11 of 397 | 795 | NCT01523587 | Trial comparisons |
| Afatinib vs Erlotinib: deaths from any cause | 77 of 392 | 71 of 395 | 787 | NCT01523587 | Trial comparisons |
| Afatinib vs Erlotinib: serious adverse events | 174 of 392 | 175 of 395 | 787 | NCT01523587 | Trial comparisons |
| Nivolumab + Ipilimumab vs Nivolumab: deaths from any cause | 92 of 125 | 105 of 127 | 252 | NCT02785952 | Trial comparisons |
| Nivolumab + Ipilimumab vs Nivolumab: serious adverse events | 78 of 124 | 58 of 123 | 247 | NCT02785952 | Trial comparisons |
| Second-line Afatinib Treatment Group vs Second-line Chemotherapy Treatment Group: Number of Patients With Severe Immune-related Adverse Events (irAEs) of Specific Interest During Second-line Treatment | 6 of 99 | 0 of 101 | 200 | NCT04552535 | Trial comparisons |
| Arm I & Arm III (Initial Treatment and Retreatment With MEDI4736) vs Arm II (Docetaxel - Closed to Accrual 4/2015): deaths from any cause | 58 of 68 | 26 of 30 | 98 | NCT02766335 | Trial comparisons |
| Arm I & Arm III (Initial Treatment and Retreatment With MEDI4736) vs Arm II (Docetaxel - Closed to Accrual 4/2015): serious adverse events | 27 of 68 | 3 of 30 | 98 | NCT02766335 | Trial comparisons |
| A: Erlotinib vs B: Docetaxel: deaths from any cause | 7 of 38 | 3 of 41 | 79 | NCT01652469 | Trial comparisons |
| A: Erlotinib vs B: Docetaxel: serious adverse events | 7 of 38 | 19 of 41 | 79 | NCT01652469 | Trial comparisons |
| Palbociclib vs Docetaxel: deaths from any cause | 28 of 32 | 10 of 10 | 42 | NCT02785939 | Trial comparisons |
| Palbociclib vs Docetaxel: serious adverse events | 14 of 32 | 0 of 10 | 42 | NCT02785939 | Trial comparisons |
| AZD4547 vs Docetaxel: deaths from any cause | 25 of 27 | 9 of 9 | 36 | NCT02965378 | Trial comparisons |
| AZD4547 vs Docetaxel: serious adverse events | 7 of 27 | 1 of 9 | 36 | NCT02965378 | Trial comparisons |
| Afatinib 40 mg + Pembrolizumab 200 mg vs Afatinib 30 mg + Pembrolizumab 200 mg: deaths from any cause | 10 of 12 | 10 of 12 | 24 | NCT03157089 | Trial comparisons |
| Afatinib 40 mg + Pembrolizumab 200 mg vs Afatinib 30 mg + Pembrolizumab 200 mg: serious adverse events | 4 of 12 | 9 of 12 | 24 | NCT03157089 | Trial comparisons |
| Afatinib 40 mg + Pembrolizumab 200 mg vs Afatinib 30 mg + Pembrolizumab 200 mg: Duration of Objective Response (DOR) | 2 of 2 | 1 of 1 | 3 | NCT03157089 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005097/comparisons